Theravance Biopharma

Trump's reelection may boost biotech innovation and M&A activity, potentially repealing the Inflation Reduction Act. Key roles in federal health agencies will influence drug pricing reforms. The Zacks Medical-Drugs industry, despite headwinds, shows promising trends with innovation in diabetes/obesity, inflammation, and neuroscience. Small drugmakers rely on collaboration partners and R&D funding, with notable stocks including Corcept Therapeutics, Madrigal Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, and Larimar Therapeutics.

DelveInsight's 'Janus Kinase (JAK) Inhibitors Pipeline Insight, 2024' report details the global pipeline, including clinical trials, therapies, MOA, ROA, and key companies like Pfizer, Incyte Corporation, and AbbVie. It highlights emerging therapies like SDC-1801 and Povorcitinib, recent approvals such as upadacitinib for nr-axSpA, and ongoing Phase III trials like Incyte's povorcitinib for hidradenitis suppurativa.

The 'Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type' report outlines market players addressing antimicrobial resistance, including drug manufacturers, biotech companies, and regulatory bodies. It highlights the role of diagnostics in combating AMR and identifies 6 key market opportunities. The report provides five-year market forecasts and profiles over 100 biotech companies.